The 2021–23 Washington budget enables consideration of pediatric rheumatologists for state loan forgiveness programs during the 2019–21 and 2021–23 cycles, making it the first state to include any rheumatologists in its loan forgiveness programs.
FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use
On Sept. 1, the U.S. Food & Drug Administration (FDA) announced that it is requiring revisions to the Boxed Warning for the Janus kinase (JAK) inhibitors Xeljanz/Xeljanz XR (tofacitinib), Olumiant (baricitinib) and Rinvoq (upadacitinib) to include information about the risks of serious heart-related events, cancer, blood clots and death.1 Recommendations for healthcare professionals will include…
ACR Guidance on Tocilizumab Allocation During Shortage
In June, the U.S. Food & Drug Administration (FDA) issued an emergency use authorization (EUA) for tocilizumab (Actemra) for treatment of hospitalized COVID-19 adults and children who are receiving systemic corticosteroids and supplemental oxygen. Since this announcement, the tocilizumab manufacturer, Genentech, has not been able to produce enough product to meet the higher demand. The…
20 Years of RA Data: First-Line Biologic & Targeted Synthetic DMARD Trends
Data from a single-center registry shines light on 20 years of trends in first-line, biologic disease-modifying anti-rheumatic drug prescriptions for patients with rheumatoid arthritis.
Rheumatology Proud: Fostering an Inclusive Environment in Academic Medicine
Everyone wants to be accepted and feel like they belong. These are innately human traits, and they don’t go away when we leave the grade school playground, high school cafeteria or university quad. We want to feel safe and accepted at work, too, and that feeling is important to professional success and effectiveness. From a…
Updates in Pediatric Lupus: Experts Discuss Advances in Lupus Nephritis Treatments, Monogenic Lupus & More
PRSYM—At the 2021 Pediatric Rheumatology Symposium (PRSYM), a session on lupus provided a robust discussion of recent advances in lupus treatments and genetic discoveries in pediatric rheumatology. Lupus Nephritis The first speaker was Shaun Jackson, MD, PhD, a pediatric nephrologist and rheumatologist and associate professor at Seattle Children’s. His presentation focused on state-of-the-art treatments in…
Vasculitis Guidelines in Focus, Part 1: The Guideline Project
Sharon A. Chung, MD, MAS, director of the vasculitis clinic at the University of California, San Francisco, served as the principal investigator of the overall vasculitis guideline effort and talks about the process here.
NIH Starts Study of COVID-19 Booster Shot in People with Autoimmune Diseases
(Reuters)—The U.S. National Institutes of Health (NIH) is testing a booster shot of COVID-19 vaccines in people with autoimmune diseases who have not responded well to the primary vaccine course. The mid-stage study will be conducted among about 600 participants aged 18 and above who have been fully vaccinated with shots from either Pfizer Inc.,…
In Memoriam: Remembering William R. Palmer, MD, MACR
William “Bill” R. Palmer, MD, MACR, passed away on Aug. 5, 2021, from highly aggressive, metastatic thyroid carcinoma. He was surrounded by his loving family. Continuing a lifelong pattern, he was courageous, dignified and loving through his last moments. I first met Bill on July 1, 1974—my first day of my medical internship at Albany…
Kaitlyn Brittan, MD: ‘Advocacy Tells Me I Have a Voice’
Rheumatology advocacy added focus and purpose to Dr. Brittan’s medical training and now, in the rheumatology division at the University of Nebraska Medical Center, strengthens her relationships with colleagues and patients alike.
- « Previous Page
- 1
- …
- 118
- 119
- 120
- 121
- 122
- …
- 800
- Next Page »